Search

Blog

We constantly analyse the legislation and regulatory information related to a specific medicine in order to appraise the context in which the company operates

We put all our knowledge into play to anticipate risks and seize every opportunity, but above all to understand the rules of the game and display our creativity with them. We spread material and information proceeding from our investigation into medicines governance and regulatory science. In fact, we deem it necessary to be aware of the complexity of the results of research, regulation and drug policy in order to be able to work in a cultural ecosystem aiming both at promoting research outcomes that are useful to patients and at encouraging politicians to protect people’s health. The wider the knowledge of each interest group, the greater their ability to interact and achieve transparency of procedures and health protection.

  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value

Bozza di documento sui criteri di valutazione per l’attribuzione dell’innovatività terapeutica

Il 12 marzo 2025, AIFA ha pubblicato la bozza del documento sui “𝗖𝗿𝗶𝘁𝗲𝗿𝗶 𝗱𝗶 𝘃𝗮𝗹𝘂𝘁𝗮𝘇𝗶𝗼𝗻𝗲 𝗽𝗲𝗿 𝗹’𝗮𝘁𝘁𝗿𝗶𝗯𝘂𝘇𝗶𝗼𝗻𝗲 𝗱𝗲𝗹𝗹’𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗶𝘁𝗮̀ 𝘁𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰𝗮 𝗲 𝘀𝘂𝗹𝗹𝗮 𝗴𝗲𝘀𝘁𝗶𝗼𝗻𝗲 ...
Read more "

AIFA-Regions Technical Coordination Table

Aggiornamento Il 9 ottobre 2025 è stata aggiornata la composizione del Tavolo tecnico AIFA-Regioni: è stata integrata la nomina della Regione Puglia, ...
Read more "

Pharma Value Report - The new European HTA Regulation

The new European Regulation on Health Technology Assessment (HTA-R) 2021/2282 officially came into force on January 12, 2025, marking a significant step ...
Read more "

Pharma Value Agenda 2025: Writing and Content

Once again this year, Pharma Value S.r.l. presents the new Agenda 2025, a project that for the past four years has been a moment of reflection ...
Read more "
Training for Astrazeneca

A unique cross-functional training experience with AstraZeneca

On 28 November 2024, Pharma Value partnered with AstraZeneca to organise an in-house training day of great innovative value. A ...
Read more "

Pharma Value at the 10th National Congress ISPOR Italy - Rome Chapter

On 4-5 December 2024, Pharma Value participated in the 10th National Congress ISPOR Italy - Rome Chapter with two scientific contributions, ...
Read more "

Pharma Value at ISPOR Europe 2024

The Pharma Value team participated in ISPOR Europe 2024, held in Barcelona from 17 to 20 November. Under the theme 'Generating Evidence ...
Read more "

Budget Law 2025: possible changes to the innovativeness criteria

Aggiornamento 20 dicembre 2024 Il 28 dicembre 2024, il Senato della Repubblica ha approvato in via definitiva la Legge di Bilancio per ...
Read more "

8th Orphan Drug Day - The Orphan Drug Comparator - Limits and the right to the best treatment

Rome, 16 October 2024 - In the context of rare diseases, orphan drugs play a key role because they treat conditions for which there are ...
Read more "
en_GB